Duloxetine is effective in treating depression in multiple sclerosis patients: An open-label multicenter study

Clinical Neuropharmacology

Volumn 36, Issue 4, 2013, Pages 114-116

  Solaro, Claudio ^a   Bergamaschi, Roberto ^b   Rezzani, Cristiana ^b   Mueller, Margit ^a   Trabucco, Erika ^a   Bargiggia, Valeria ^b   Dematteis, Francesca ^c   Mattioda, Alessandra ^c   Cimino, Vincenzo ^d   Restivo, Domenico ^e   Patti, Francesco ^d   Cavalla, Paola ^c  

^a Department Head Neck UO Neurology ASL 3 Genovese ^*  (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e Hospital G Garibaldi Catania   (Italy)

Author keywords

Depression; Duloxetine; Multiple sclerosis

Indexed keywords

BETA INTERFERON; DULOXETINE; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; DEPRESSION; DISEASE DURATION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE IMPACT SCALE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; THERAPY EFFECT; TREATMENT DURATION; VITAL SIGN;

EID: 84880783549     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182996400     Document Type: Article

References (25)

1. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 1990;47: 98-104.
2. Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41: 1193-1196.
3. Schiffer RB, Babigian HM. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. An epidemiologic study. Arch Neurol 1984;41: 1067-1069.
4. Rao SM, Huber SJ, Bornstein RA. Emotional changes with multiple sclerosis and Parkinson's disease. J Consult Clin Psychol 1992;60: 369-378.
5. Chwastiak L, Ehde DM, Gibbons L, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002;159: 1862-4868.
6. Janssens AC, Buljevac D, Van Doorn PA, et al. Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study. Mult Scler 2006;12: 794-801.
7. Feinstein A. Multiple Sclerosis and depression. Mult Scler 2011;17: 1276-1281.
8. Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Library 2011; CD007295.
9. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990;147: 1493-1497.
10. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 2008;30: 40-48.
11. Cetin K, Johnson KL, Ehde DM, et al. Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample. Mult Scler 2007;13: 1046-1053.
12. Patten SB, Metz LM. Depression in multiple sclerosis. Psychother Psychosom 1997;66: 286-292.
13. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. 2002. J Clin Psychiatry 2002;63: 308-315.
14. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63: 225-231.
15. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 2004;4: 11.
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005;58: 840-846.
17. American Psychiatric Association. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Press Inc; 1994.
18. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69(6): 942-949.
19. Scott TF, Nussbaum P, McConnell H, et al. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995;17: 421-422.
20. Benedetti F, Benedetti Campori E, Colombo C, et al. Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci 2004;16: 364-366.
21. Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci 1999;11: 271-273.
22. Koran LM, Aboujaoude EN, Gamel NN. Duloxetine treatment of dysthymia and double depression: an open-label trial. J Clin Psychiatry 2007;68: 761-765.
23. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67: 1411-1412.
24. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005;11: 328-337.
25. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6: 181-185.